Australia markets open in 1 hour 21 minutes

bluebird bio, Inc. (BLE.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
15.900.00 (0.00%)
At close: 05:13PM CEST
Full screen
Previous close15.90
Open15.85
Bid0.00 x 12000
Ask0.00 x 12000
Day's range15.85 - 15.90
52-week range15.31 - 49.99
Volume70
Avg. volume103
Market cap1.075B
Beta (5Y monthly)1.69
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions

    SOMERVILLE, Mass., June 10, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of betibeglogene autotemcel (beti-cel) for the treatment of people with beta-thalassemia who require regular red blood cell (RBC) transfusions.

  • Business Wire

    FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

    SOMERVILLE, Mass., June 09, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age who do not have an available and willing human leukocyte antigen (HLA)-matched sibling hematopoietic stem cell (HSC) donor.

  • Business Wire

    bluebird bio stock trading halted today June 9th and tomorrow June 10th

    SOMERVILLE, Mass., June 09, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that Nasdaq has halted trading of the company’s common stock on Thursday, June 9 and Friday, June 10, 2022. The U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is meeting to discuss the biologics licensing applications (BLAs) for betibeglogene autotemcel (beti-cel) and elivaldogene autotemcel (eli-cel).